Robenidine Veterinary Grade API is the hydrochloride salt of 1,3-bis[(4-chlorobenzylidene)amino]guanidine, supplied for the manufacture of tablets, injections, capsules, powders, granules, premix, and solutions. The CAS registry number is 25875-51-8; the molecular formula C₁₅H₁₃Cl₂N₅·HCl corresponds to a molecular weight of 370.66 g/mol. Material released against veterinary API controls is an off-white to pale yellow crystalline powder with a dried-basis assay commonly controlled in the range 98.0–102.0% by high-performance liquid chromatography. The product is available as standard crystalline powder and micronized powder. The micronized grade is controlled by laser diffraction according to ISO 13320-1:2020 to a D90 below 25 µm; the standard grade is used in feed premix work where carrier adhesion governs distribution. Robenidine is a synthetic non-ionophore guanidine derivative intended for coccidiosis control in poultry and rabbits; it is not interchangeable with fermentation-derived polyether ionophores and must be handled under veterinary drug-manufacturing controls rather than as a finished feed.

The choice between standard and micronized models affects downstream unit operations. Micronized material improves suspension particle-size control and dissolution surface area but can reduce flow and increase dusting; standard crystalline powder is easier to blend into dry feed premixes but may require wet granulation for tablet or capsule intermediates. The appropriate model is therefore dictated by the final dosage form and the available blending and drying equipment, not by the API content alone.

How Does the Hydrochloride Salt Distribute Across Solid, Liquid, and Feed Manufacturing Routes?

For tablet compression, direct compression is generally limited by the needle-like crystal habit, low bulk density, and flow variability of robenidine HCl. Dry granulation by roller compaction followed by milling to a granule D50 of 150–250 µm is used to improve flow and reduce segregation; tablet hardness is commonly set at 80–120 N for immediate-release matrices, with disintegration tested according to Ph.Eur 2.9.1 or USP <701>. Capsule filling of the same granulated intermediate on tamping-pin or dosator equipment should maintain fill-weight variability below 2% relative standard deviation. For powders and granules intended for oral dosing, wet granulation with povidone or pregelatinised starch reduces dusting, but the drying step must be controlled below 55°C and the final loss on drying held below 1.0% to limit hydrolysis of the Schiff base linkages.

Parenteral solution development is constrained by the near-insolubility of the hydrochloride salt in water at neutral pH. Injectable presentations are therefore developed as sterile suspensions or as non-aqueous vehicles where regulatory monographs permit. Suspension concentrates require particle-size reduction to maintain syringeability through a 25 G needle and typically include wetting agents and viscosity modifiers; terminal sterilisation is selected in accordance with Ph.Eur 5.1.1 or equivalent. Published data for specific injectable robenidine formulations are limited; pH, polymorph, and impurity stability should be assessed on a formulation-specific basis.

For premix production, the low final feed inclusion rate imposes a geometric dilution sequence. A representative 0.5% w/w premix of robenidine HCl is prepared by blending 5.0 kg of API with 995.0 kg of suitable carrier; incorporation of 6.6 kg of this premix per metric tonne yields a 33 mg/kg chicken ration. Homogeneity release is assessed by ten discrete sample points and should demonstrate an assay coefficient of variation below 5%. Production-scale ribbon blenders operated at 10–15 rpm require periodic dead-spot inspection at seal and discharge regions because segregation can occur when the API particle size differs substantially from the carrier.

For liquid feed or drench applications, solubility in the selected vehicle must be confirmed before scale-up. The hydrochloride salt is not freely soluble in water; non-aqueous or co-solvent systems are more common in experimental liquid preparations. Where a true solution is claimed, it should be protected from light and held at a pH that avoids free-base formation and Schiff base hydrolysis. Final solutions should be assayed after 24 h and 48 h at 25°C and 40°C to establish chemical stability before distribution. Powders for extemporaneous reconstitution face similar constraints; a suspension, not a solution, is usually the expected dosage form unless solubility data demonstrate otherwise.

Release Limits Aligned With Pharmacopoeial and Residue-Control Frameworks

Because robenidine is a low-dose veterinary active, release controls address chemical purity, particle-size, and residue-forming potential. The following table is representative of a compendial-suitable panel; acceptance values are set by the relevant marketing authorization, pharmacopoeial monograph, or manufacturer specification, and published data for this specific configuration is limited where no harmonised monograph exists.

The HPLC method used for release and stability should resolve the intact guanidine derivative from its principal hydrolytic marker, 4-chlorobenzaldehyde, and from the free base. System suitability criteria typically include resolution of not less than 2.0, tailing factor not more than 2.0, and replicate injection RSD not more than 2.0%. The method should be validated for specificity, linearity, accuracy, precision, and robustness according to ICH Q2(R2) or current VICH guidance. For feed premix release, a combined potency and homogeneity protocol is required because composite sampling alone can mask segregation. Retention samples should be stored at 25°C/60% RH and 40°C/75% RH according to ICH stability conditions for climatic zones I and II; long-term data for a given API lot should be obtained from the specific manufacturer.

In comparison with polyether ionophore coccidiostats such as monensin, salinomycin, and lasalocid, robenidine is a synthetic guanidine derivative rather than a fermentation-derived ion-carrier. Ionophores form lipid-soluble cation complexes and modify ionic gradients across the cell membranes of Eimeria, while robenidine is proposed to interfere with parasite energy metabolism, although the exact molecular target is less completely characterised. This mechanistic distinction means robenidine should be managed as a separate chemical class in rotation programmes and is not interchangeable with ionophore-containing premixes on a milligram-equivalent basis. In contrast to nicarbazin, which is not authorised for rabbits in several regulatory systems, robenidine has rabbit label indications in selected jurisdictions; exact species approval, maximum residue limits, and withdrawal periods are determined by national veterinary drug registers.

Robenidine also differs from triazine coccidiostats such as diclazuril and toltrazuril. Triazines act on mitochondrial electron transport and are often used in short-course therapeutic or control programmes, whereas robenidine is used mainly as a prophylactic coccidiostat in medicated feed or drinking water. Cross-resistance between robenidine and triazines is not consistently documented, but repeated use of a single anticoccidial class can select reduced-sensitivity Eimeria strains. Published data for specific field isolates are limited, and susceptibility monitoring should be performed when reduced performance is observed. Robenidine should also not be confused with sulfonamide-based coccidiostats or with amprolium, which acts as a thiamine antagonist; the analytical method for robenidine does not cross-react with those agents, and segregation and carryover controls must therefore be chemical-specific rather than generic.

When a Premix Requires Segregation-Resistant Granulation and Residual Benzaldehyde Control

Batch-to-batch variance in tapped density, angle of repose, and particle-size distribution should be monitored when the same API lot is intended for both premix and tablet manufacture. A low-dust granulated premix intermediate can be produced by wet binding with hydroxypropyl methylcellulose or starch paste, followed by fluid-bed drying at 45–55°C until loss on drying is below 1.0%. Granulation reduces dusting and improves carrier adhesion, but it can also prolong release if the binder level is excessive; dissolution testing according to USP <711> is therefore required for tablet and capsule formulations even when the API is highly potent at low dose.

Residual 4-chlorobenzaldehyde is the principal degradation marker to control in stability studies. Hydrolysis of the Schiff base is accelerated by heat, moisture, and strongly acidic or basic conditions. The API should therefore not be dry-mixed with strongly alkaline feed components, and liquid formulations should avoid prolonged exposure to pH values below 2 or above 9 unless stability data demonstrate otherwise. Oxidative conditions can also generate additional impurities; formulations that include reducing agents or antioxidants should be confirmed by forced-degradation studies before the commercial specification is fixed.

For a 0.5% w/w premix, carryover between batches is a critical control point because the next non-medicated feed can be contaminated at analytically significant concentrations. Cleanout procedures should be validated by swab or rinse sampling and a limit derived from the lowest authorised dose; published data for specific equipment trains are limited, but the target carryover limit should be defined by the manufacturer in the site master file. Occupational handling should assume that fine particulate can cause respiratory irritation. Dedusting or local exhaust ventilation is required during open transfer of micronized material, and operators handling the API should use suitable respiratory protection and protective clothing according to the safety data sheet. The compound should not be discharged into watercourses, and waste containing robenidine should be managed as veterinary medicinal waste rather than general feed waste.

Each batch should be accompanied by a certificate of analysis that includes the batch number, manufacturing date, retest date, storage condition, and results for appearance, identification, assay, related substances, loss on drying, residue on ignition, residual solvents, and particle-size where applicable. If a batch is intended for multiple dosage forms, the certificate should state which physical grade has been released. A declaration of animal-origin materials should be provided to satisfy feed-chain audits; robenidine itself is not of animal origin, but the carrier used for premix intermediates may be.